



A Retrospective Study Evaluating the Impact of Loco-regional Surgery in Metastatic Breast Cancer at the Time of Initial Diagnosis

Thesis submitted for partial fulfillment of master degree in Clinical
Oncology and Nuclear Medicine

Presented by,

Mohammad Mostafa Mostafa Kamal Darwish

M.B, B.Ch,

Under supervision of,

Prof. Dr. Soheir Sayed Ismaeil

Professor of Clinical Oncology and Nuclear Medicine,
Faculty of Medicine - Ain Shams University

Dr. Wesam Reda El Ghamry

Lecturer of Clinical Oncology and Nuclear Medicine
Faculty of Medicine - Ain Shams University

Dr. Mai Mohammad Ali Ezz El Din

Lecturer of Clinical Oncology and Nuclear Medicine
Faculty of Medicine - Ain Shams University

**Department of Clinical Oncology and Nuclear Medicine
Ain Shams University
2016**

List of Contents

	PAGE
1. LIST OF ABBREVIATIONS.....	I
2. LIST OF TABLES	V
3. LIST OF FIGURES	VI
4. REVIEW OF LITERATURE	1
I. EPIDEMIOLOGY	1
II. RISK FACTORS	13
III. PROGNOSTIC FACTORS.....	24
IV. PATHOLOGY	42
V. SCREENING AND DIAGNOSIS	57
VI. MANAGEMENT	67
5. PATIENTS AND METHODS	85
6. RESULTS.....	90
7. DISCUSSION.....	108
8. SUMMARY AND CONCLUSION	117
9. REFERENCES	119
10. ARABIC SUMMARY	

List of Abbreviations

· 3D	Three Dimensional
· ACS	American Cancer Society
· AJCC	American Joint Committee on Cancer
· AR	Androgen Receptor
· ASIR	Age-Standardized Incidence Rate
· ASTRO	American Society for Radiation Oncology
· BCAC	Breast Cancer Association Consortium
· BCS	Breast Conservative Surgery
· BCSS	Breast Cancer-Specific Survival
· BLBC	Basal-Like Breast Cancer
· BMI	Body Mass Index
· BRCA1/2	BReast CAncer 1 & 2
· CA 15-3	Cancer Antigen 15-3
· CCL2	C-C motif Ligand 2
· CDK4/6	Cyclin-Dependent Kinases 4 & 6
· CEA	CarcinoEmbryonic Antigen
· CK	CytoKeratins
· CR	Complete Response
· CTCs	Circulating Tumor Cells
· CXCL12	C-X-C motif chemokine 12
· DCIS	Ductal Carcinoma InSitu
· DCIS	Ductal Carcinoma <i>In Situ</i>
· DFI	Disease Free Interval
· DIN	Ductal Intraepithelial Neoplasia
· DMFS	Distant Metastasis Free Survival
· ECM	ExtraCellular Matrix
· ECOG	Eastern Cooperative Oncology Group score
· EFS	Event-Free Survival

· EMA	Epithelial Membrane Antigen
· ER	Estrogen Receptor
· FES	¹⁸ F-fluoroEStradiol
· FFTP	First Full-Term Pregnancy
· FH	Family History
· FISH	Fluorescent In Situ Hybridization
· GEP	Gene Expression Profiling
· Her2	Human Epidermal Growth Factor Receptor 2
· HIS	Human Invasion Signature
· HR	Hazard Ratio
· HR	Hormonal Receptor
· IDC	Invasive Ductal Carcinomas
· IHC	ImmunoHistoChemical assessment
· IL-1 β	InterLeukin 1 beta
· ILC	Invasive Lobular Carcinomas
· LCIS	Lobular Carcinoma InSitu
· LFS	Li-Fraumeni Syndrome
· LIN	Lobular Intraepithelial Neoplasia
· LVI	Lymphatic Vascular Invasion
· MBC	Metastatic Breast Cancer
· MHT	Menopausal Hormonal Therapy
· MP	MammaPrint
· MRI	Magnetic Resonance Imaging
· MRM	Modified Radical Mastectomy
· mTOR	mammalian Target Of Rapamycin
· NCCN	National Comprehensive Cancer Network
· NCI	National Cancer Registry
· NE	Not Estimated
· NOS	Not Otherwise Specific
· NST	No Special Type

· ODX	Oncotype DX™
· OS	Overall Survival
· PD	Progressive Disease
· PET	Positron Emission Tomography
· PFS 1	Time for the first progression
· PFS	Progression Free Survival
· PNI	Perineural Invasion
· PR	Partial Response
· PR	Progesterone Receptor
· PS	Performance Status
· RANKL	Receptor Activator of Nuclear factor Kappa-B Ligand
· RCTs	Randomized Controlled Trials
· RECIST	Response Evaluation Criteria In Solid Tumors
· RFA	RadioFrequency Ablation
· RR	Relative Risks
· RS	Recurrence Score
· SBRT	Stereotactic Body RadioTherapy
· SD	Stable Disease
· SDF1	Stromal cell-Derived Factor 1
· SEER	Surveillance, Epidemiology, and End Results
· SERD	Selective Estrogen Receptor Down-regulator
· SMA	Smooth Muscle Actin
· SPECT	Single Photon Emission CT
· SPSS	Statistical Package for Social Science
· SREs	Skeletal-Related Events
· SRS	Stereotactic RadioSurgery
· TACE	Transcatheter Arterial ChemoEmbolization
· TDLU	Terminal Duct-Lobular Unit
· TMEM	Tumor MicroEnvironment of Metastasis
· TNBC	Triple Negative Breast Cancer

- TNM Tumor–Node–Metastases staging system
- UICC Union Internationale Contre le Cancer
- UK United Kingdom
- VEGF Vascular Endothelial Growth Factor
- VEGFR Vascular Endothelial Growth Factor Receptor
- WBRT Whole Brain Radiotherapy
- WHO World Health Organization

List of Tables

Table	Title	Page
1	Factors That Increase the Relative Risk for Breast Cancer in Women.	14
2	Relative risk (RR) of breast and ovarian cancers associated with <i>BRCA1/2</i> mutations according to ages.	16
3	Classical prognostic factors in primary breast cancer.	24
4	Breast cancer subtypes according to molecular taxonomy.	35
5	Mirel's scoring system for the risk of pathologic fracture.	77
6	Demographic, clinical and tumor characteristics of patients who presented with stage IV breast cancer.	90
7	Effect of surgery on the OS of the patients.	95
8	Effect of age and menopausal status in both groups on the OS.	96
9	Effect of primary tumor size staging, and nodal staging on OS of patients in surgical group.	97
10	Effect of pathological tumor grade on the survival of patients in surgical and non-surgical group.	98
11	Effect of ER status on OS in both groups.	99
12	Effect of Her2 status on OS in both groups.	100
13	The observed significant survival benefit of bone-only.	102
14	Effect of oligometastases on the OS of patients in the surgical and non-surgical group.	103
15	The effect of surgery for the primary tumor on the progression free survival (PFS), including the time to first progression (PFS 1) of the patients with de novo metastatic breast cancer.	105

List of Figures

Fig.	Title	Page
(1.1)	Breast Cancer Incidence and Mortality Rates by World Area in 2012.	3
(1.2)	Cumulative percent of breast cancer in females, SEER17, 2000-2005.	4
(1.3)	Age-specific breast cancer incidence rates, all ages, all races, SEER data 2000-2006.	5
(1.4)	Age-specific incidence rates for breast cancer in Egypt 2008–2011.	6
(1.5)	Trends of the most common cancers in females from 2002-2010 in NCI, showing breast cancer the most common cancer in females by far.	6
(1.6)	Age specific incidence rates of breast cancer in NCI 2002-2010.	7
(1.7)	Tumor grades according to <i>Egypt's National Cancer Registry for Aswan, 2008; for Demiatta & El-Minya, 2009.</i>	8
(1.8)	Tumor stage in Aswan according to the <i>Egypt National Cancer registry for Aswan, 2008.</i>	8
(1.9)	Tumor stage in Damietta according to the <i>Egypt National Cancer registry for Damietta, 2009.</i>	9
(1.10)	Tumor stage in El-Minya according to the <i>Egypt National Cancer registry for El-Minya, 2009.</i>	10
(1.11)	Estimated number of cases in Egypt (2013–2050).	10
(1.12)	Estimated number of cases in Egypt (2013–2050) and causes of the increase in cases.	11
(3.1)	Kaplan–Meier analysis for event-free survival (EFS) according to patients' age at diagnosis. Patients were stratified into three age groups (<40, 40–50 and >50 years).	26
(3.2)	Breast cancer stages of the American Joint Committee on Cancer and International Union Against Cancer (AJCC/UICC), with associated 10-year survival.	29

Fig.	Title	Page
(3.3) A	Overall survival in breast cancer patients with (LVI+) or without (LVI-) lymphovascular invasion.	31
(3.3) B	Disease-free survival in breast cancer patients with (LVI+) or without (LVI-) lymphovascular invasion.	31
(3.4)	Invasion of vessels (lymphatic or vascular) by malignant cells.	32
(3.5)	KaplaneMeier curves for distant metastasis-free survival (DMFS) and breast cancer-specific survival (BCSS) by MammaPrint Risk for 173 patients with 4-9 positive lymph nodes. A. DMFS, B. BCSS.	40
(4.1)	Section of the nipple showing stratified squamous epithelium and densely fibrotic dermis.	43
(4.2) A	High power view of acini present in a normal lobule.	44
(4.2) B	Calponin immunostating highlighting the myoepithelial cells in the lobule.	44
(4.3)	Intraepithelial neoplasia.	46
(4.4)	Invasive ductal carcinoma infiltrating the fatty tissue of the breast.	48
(4.5)A	Invasive Ductal Carcinoma (IDC), grade I.	49
(4.5)B	Invasive Ductal Carcinoma (IDC), grade II.	49
(4.5) C	Invasive ductal NST carcinoma, grade III with no evidence of glandular differentiation.	49
(4.6)	Invasive ductal carcinoma, pleomorphic variant.	50
(4.7)	In situ and invasive lobular carcinoma.	51
(4.8)	Mixed infiltrating ductal and infiltrating lobular carcinoma.	52
(4.9)	Medullary carcinoma.	53
(4.10)	Tubular carcinoma.	54
(4.11)A	Mucinous carcinoma, hypercellular variant.	56
(4.11) B	Mucinous carcinoma, hypocellular variant.	56

Fig.	Title	Page
(5.1)	3D mammographic image of breast cancer.	61
(5.2)	MRI of a breast cancer.	61
(5.3)	Comparison between planar bone scan, SPECT and PET in a patient with bone metastases.	63
(5.4)	Images measuring glucose activity and ER expression in metastatic breast cancer.	64
(6.1)	Kaplan–Meier curves illustrating overall survival for patients with de novo stage IV versus relapsed disease.	68
(6.2)	Kaplan–Meier curves illustrating overall survival for patients with de novo stage IV disease and those with relapsed disease. Patients with relapsed disease are stratified by disease-free interval.	69
(6.3)	Kaplan-Meier curves illustrating the overall survival and cancer-specific survival for patients with metastatic breast cancer undergoing primary breast surgery vs. non-surgical treatment.	71
(7.1)	Kaplan-Meier curve showing the significant improved overall survival among patients underwent primary tumor surgery, when compared to those who did not do surgery.	95
(7.2)	Effect of surgery on OS of patients.	95
(7.3)	Pie-chart of pathologic nodal status in the patients of surgical group.	98
(7.4)	Difference between effect of ER status on OS in both surgical and non-surgical groups.	99
(7.5)	Distribution of ER status among the patient population.	100
(7.6)	Difference between effect of Her2 status on OS in both surgical and non-surgical groups.	101
(7.7)	Distribution of Her2 status among the patient population.	101
(7.8)	The observed survival benefit of bone-only	102

Fig.	Title	Page
	seconadaries than other sites, with this benefit more obvious in the surgical group.	
(7.9)	Kaplan-Meier curve showing the significant improved overall survival among patients with oligometastases, when compared to those with wide spread metastases.	104
(7.10)	Patients underwent primary tumor surgery have a significant better mean PFS than patients didn't undergo surgery.	105
(7.11)	Kaplan-Meier curve showing the significant increase in time to first progression (PFS 1) in surgical group compared to non-surgical group.	106

Abstract

Breast cancer is the most common malignant tumor among women worldwide. Despite the advances in the diagnosis and management of breast cancer, 6–10% of affected patients present metastatic breast cancer at diagnosis and 30–40% will develop metastases during the evolution of their disease. The appearance of metastases, as a sign of incurability, constitutes a major problem of care. The recent therapeutic strategies and emergence of new drugs have not only helped to extend the median survival time (around 30 months now) but also to improve the quality of patients' lives. The mainstay of treatment in metastatic breast cancer is systemic therapy, which includes chemotherapy, endocrine therapy and targeted therapy. Traditionally, loco-regional treatment (surgery or radiotherapy) has been used only for control of fungation and bleeding. However, metastatic breast cancer patterns have undergone some changes with increasingly sensitive imaging modalities, resulting in potential stage migration. This allows clinicians to better identify metastatic breast cancer patients with an improved prognosis and the potential to benefit from a more aggressive loco-regional or systemic treatment approach.

Our study analyzed retrospectively the impact of loco-regional surgery on the outcome of patients with breast cancer found to be metastatic at their initial diagnosis, and found a clear survival benefit in the patients underwent surgery for their primary breast tumor. The results of the current study contribute to the growing body of literature addressing the question of whether surgical resection of the primary tumor in patients presenting de novo with stage IV disease improves survival. Findings from this and other studies provide support for a prospective, randomized trial to more definitively test the hypothesis that better control of local disease in stage IV breast cancer patients will improve survival. Other important questions that should be addressed are the optimal timing of surgery, the optimal chemotherapy regimen, and methods of and indications for resection of site(s) of metastasis.

We do not at present recommend 'routine' breast surgery or definitive local treatment in women with known metastatic breast cancer receiving standard palliative treatments.

Keywords : ODX: Oncotype DX™, MRM: Modified Radical Mastectomy; TNM: Tumor–Node–Metastases staging system

Epidemiology

The global burden:

Cancer constitutes a huge burden on society in more and less economically developed countries alike. The incidence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, physical inactivity, overweight, and changing reproductive patterns associated with urbanization and economic development. (*Torre et al., 2015*)

Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide, with breast cancer remaining the leading cause of cancer death among females in less developed countries (Fig 1.1). (*Torre et al., 2015*)

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females worldwide, with an estimated 1.7 million cases and 521,900 deaths in 2012. Breast cancer accounts for 25% of cancer cases and 15% of cancer deaths among females. More developed countries account for about one-half of all breast cancer cases and 38% of deaths. International variation in breast cancer incidence rates reflects differences in the capability of early detection as well as presence of risk factors. (*Schottenfeld, 2006*)

In the timeline between 1980 and the late 1990s, breast cancer incidence rates rose approximately 30% in Western countries, likely because of changes in reproductive factors and the use of menopausal hormonal therapy (MHT) and more recently because of increased screening. Declining incidence rates in those countries in the early 2000s have been attributed to the reduced use of MHT. Beyond changes in MHT use, declining or

stable incidence rates in Western countries may also be due to plateaus in participation in mammographic screening. (*DeSantis et al., 2011; Youlden et al., 2012*)

Concerning breast cancer death rates, they have been stable or decreasing since around 1990 in Northern America and higher-resource European countries. These reductions have been attributed to early detection through mammography and improved treatment, although the respective contributions of each are unclear. Breast cancer incidence rates have been rising in many countries in South America, Africa, and Asia. The reasons are not completely understood but likely reflect changing reproductive patterns, increasing obesity, decreasing physical activity, and some breast cancer screening activity. Mortality rates in these countries are also increasing, most likely due to lifestyle changes associated with westernization compounded by the delayed introduction of effective breast cancer screening programs and, in some cases, limited access to treatment. (*Bosetti et al., 2012; Autier et al., 2011*)

Approximately 5% to 10% of breast cancers are metastatic at diagnosis; of these, approximately one-fifth will survive 5 years, depending on prognostic factors, up to 30% of node-negative and up to 70% of node-positive breast cancers will relapse. The prevalence of metastatic disease is high because many women live with this disease for several years. (*Cardoso et al., 2012*)

In the United States, approximately 6-10% of new breast cancer cases are initially Stage IV or metastatic. This is sometimes called "de novo" metastatic disease, meaning from the beginning. For 2012 this means new cases of Stage IV were in the range of 13,776 - 22,096. (*American Cancer Society (ACS) Cancer Facts and Figures 2012*)

Age distribution:

Half of breast cancers are diagnosed within the screening age bracket, which is between 50 and 69 years, while around 6.6% of all breast cancer cases are diagnosed in women less than 40 of age, 2.4% in women less than 35, and 0.65% in women less than 30; if plotted on a curve, the cumulative incidence of breast cancer seems to follow an exponential function below the age of 40 after which it seems to rise linearly. (Fig. 1.2 & 1.3) (*Anders et al., 2009; Benson et al., 2012*)




Fig (1.1): Breast Cancer Incidence and Mortality Rates by World Area in 2012. (*Torre et al., 2015*)

A statistically significant increase (1976–2009) has been reported in the age-standardized incidence rate (ASIR) for distant stage (metastatic) breast cancer diagnosed in women at age 25–39